RNA editing alterations define manifestation of prion diseases.
Eirini KanataFranc LlorensDimitra DafouAthanasios DimitriadisKatrin ThüneKonstantinos XanthopoulosNikolaos BekasJuan Carlos EspinosaMatthias SchmitzAlba Marín-MorenoVincenzo CapeceOrr ShormoniOlivier AndréolettiStefan BonnJuan-Maria TorresIsidro FerrerInga ZerrTheodoros SklaviadisPublished in: Proceedings of the National Academy of Sciences of the United States of America (2019)
Prion diseases are fatal neurodegenerative disorders caused by misfolding of the normal prion protein into an infectious cellular pathogen. Clinically characterized by rapidly progressive dementia and accounting for 85% of human prion disease cases, sporadic Creutzfeldt-Jakob disease (sCJD) is the prevalent human prion disease. Although sCJD neuropathological hallmarks are well-known, associated molecular alterations are elusive due to rapid progression and absence of preclinical stages. To investigate transcriptome alterations during disease progression, we utilized tg340-PRNP129MM mice infected with postmortem material from sCJD patients of the most susceptible genotype (MM1 subtype), a sCJD model that faithfully recapitulates the molecular and pathological alterations of the human disease. Here we report that transcriptomic analyses from brain cortex in the context of disease progression, reveal epitranscriptomic alterations (specifically altered RNA edited pathway profiles, eg., ER stress, lysosome) that are characteristic and possibly protective mainly for preclinical and clinical disease stages. Our results implicate regulatory epitranscriptomic mechanisms in prion disease neuropathogenesis, whereby RNA-editing targets in a humanized sCJD mouse model were confirmed in pathological human autopsy material.
Keyphrases
- endothelial cells
- crispr cas
- mouse model
- induced pluripotent stem cells
- multiple sclerosis
- end stage renal disease
- chronic kidney disease
- genome wide
- pluripotent stem cells
- stem cells
- single cell
- dna methylation
- newly diagnosed
- early onset
- functional connectivity
- skeletal muscle
- small molecule
- late onset
- subarachnoid hemorrhage
- fluorescent probe
- binding protein
- amyotrophic lateral sclerosis